Spending for high-priced specialty drugs for diseases such as cancer, HIV and hepatitis C is expected to rise dramatically next year, and large companies hope to put controls in place to help keep their costs down, according to a new survey.
from WebMD Health http://ift.tt/1DNgjri
via IFTTT